Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative therapies work by mimicking the natural actions of GLP-1, a hormone secreted by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these agents increase insulin release and reduce glucagon

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant recognition. These medications offer promising approaches for controlling blood sugar levels and could improve the lives of individuals living with diabetes. This novel class